Blood GFAP and NfL predict dementia years ahead
In 48,542 UK Biobank participants followed ~13 years, elevated plasma GFAP and NfL preceded dementia up to 15 years and improved prediction beyond CAIDE/DRS risk scores (AUC up to ~0.89).
Source
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
Study at a glance
- Design
- Cohort — UK Biobank prospective plasma GFAP/NfL with registry dementia follow-up
- N
- N=48542 · 1,312 incident all-cause dementia over ~13 years
- Population
- UK Biobank adults with baseline Olink plasma GFAP and NfL
- Outcome
- Incident all-cause dementia / ADRD HRs and prediction AUC for GFAP and NfL
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Prospective analysis of 48,542 UK Biobank adults with Olink plasma GFAP and NfL (NPX units) at baseline (2006–2010), followed through November 2022 for registry-based dementia. Authors used Cox models, cognition regressions, genetic correlations (AD-GRS, APOE*E4), and leave-one-region-out prediction validation.
What they found
Over 13.18 ± 2.42 years, 1,312 incident all-cause dementia cases occurred. GFAP >0.363 NPX linked to HR 2.25 for all-cause dementia (model 3); NfL >0.353 to HR 1.98. Proteins rose up to 15 years before diagnosis. DRSm plus GFAP/NfL reached AUC 0.867 (all-cause dementia) and 0.892 (ADRD). AD genetic risk correlated with both proteins.
The limits
What it doesn't show
UK Biobank is healthier and mostly White; 97.7% had only baseline protein measures. GFAP/NfL are nonspecific—elevated in many neurological conditions. Registry dementia may miss mild cases.
Key terms
- GFAP
- Glial fibrillary acidic protein—peripheral marker of astrocyte activation/neuroinflammation.
- NfL
- Neurofilament light chain—marker of axonal/neuronal injury.
- NPX
- Olink normalized protein expression on log2 scale.
- C-index / AUC
- Discrimination metrics for dementia prediction models.
- CAIDE / DRSm
- Established dementia risk scores compared with and without biomarkers.
- APOE*E4
- Major genetic Alzheimer risk allele; correlated with GFAP and NfL levels.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Study sample size?
Common questions
How early did proteins rise?
GFAP and NfL were elevated up to 15 years before dementia diagnosis.
All-cause dementia HR for high GFAP?
HR 2.25 (95% CI 1.96–2.58) when GFAP exceeded 0.363 NPX in model 3.
Did biomarkers improve existing risk scores?
Yes—adding GFAP and NfL to DRSm raised AUC to 0.867 for all-cause dementia.
Are these Alzheimer-specific?
No—they are nonspecific; authors adjusted extensively but note overlap with other brain disorders.
More on Diagnostic accuracy